MedTrace Logo

Dexmedetomidine in IVRA

NCT05123170 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 90

Last updated 2022-01-18

No results posted yet for this study

Summary

A prospective randomized controlled double-blinded study will be conducted on 90 patients assigned randomly into three equal groups,

Conditions

  • Regional Anesthesia Morbidity

Interventions

DRUG

Dexmedetomidine Injectable Solution [Dexdomitor]

two different doses of dexemedetomidine (0.25 μg /kg and 0.5 μg/kg) as adjunct to lignocaine in intravenous regional anesthesia for upper limb orthopedic surgeries

DRUG

Lidocaine IV

Intravenous regional anaesthesia

Sponsors & Collaborators

  • Menoufia University

    lead OTHER

Principal Investigators

  • Sadek AM Sadek, MD · Menoufia University

Study Design

Allocation
RANDOMIZED
Purpose
DIAGNOSTIC
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
20 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2020-02-28
Primary Completion
2021-03-25
Completion
2021-06-20
FDA Drug
Yes

Countries

  • Egypt

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05123170 on ClinicalTrials.gov